Document Type : Review Articles
Authors
1
Internal medicine, Faculty of medicine, Zagazig university, Zagazig, Egypt
2
Head of Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3
Department of clinical pathology, Faculty of Medicine, zagazig university
4
Internal Medicine Department, Faculty of Medicine, Zagazig university
5
Lecturer of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig Egypt
Abstract
Background: Due to a cascade of mutations that occur throughout the intricate hematopoiesis process, acute leukemia develops. Myeloid cells and lymphoid cells (B- and T lymphocytes) are the two main cell lineages that all pluripotent cells in the bone marrow multiply into. Nowadays, CD9 can be found expressed in many different kinds of cells and tissues, several cell types, including malignant cells, stromal cells, epithelial cells, endothelial cells, and hematopoietic cells. We intended to outline possible roles in the Possible Relationship between CD9 and acute leukemia. An intriguing strategy to eradicate LSCs and avoid relapses in the AML could involve focusing on CD9, this could be accomplished through the utilization of the chimeric antigen receptor (CAR) T-cell therapy or monoclonal antibodies. Because CD9 is expressed on monocytes and these cells are involved in the AML by generating interleukin 1, reducing their numbers could be an intriguing prospect in this disease
Keywords
Main Subjects
)
View on SCiNiTO